TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3666663
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg diltiazem tablet (one tablet bid for 7 days)
Study: 3666663
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg diltiazem tablet (two tablets bid for 7 days)
Study: 29101186
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction <20 mm Hg
Study: 29101186
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction between 20 and <40 mm Hg
Study: 29101186
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (target <140 mm Hg)
Study: 24720376
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg bid for 8 weeks
Study: 22848894
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implant-supported prosthesis (test group)
Study: 15977096
Drug: Ropivacaine 0.2
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2 % plus 1 mg/kg tramadol HCl (Group RT)
Study: 15977096
Drug: Ropivacaine 0.2
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2 % plus 0.1 mg/kg morphine HCl (Group RM)
Study: 31093952
Drug: TNHH 0.2–1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNHH 0.2–1.8 mg/kg
Study: 26399225
Drug: Tailored behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored behavioural medicine treatment (EXT)
Study: 26399225
Drug: Exercise-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-based treatment (CT)
Study: 31693129
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid
Study: 15683372
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg)
Study: 9658616
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine (3 standard injections at one month interval)
Study: 18238740
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) therapy
Study: 27126371
Drug: Reactive soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive soft tissue was debrided before implant placement (Group A)
Study: 23074313
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of beta-lactam antibiotics
Study: 23944203
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus administration of beta-lactam antibiotics
Study: 12969102
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (50 micro g) plus plain bupivacaine (10 mg)
Study: 12969102
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine (10 mg) with saline (control)
Study: 3885424
Drug: isoxicam 200
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isoxicam 200 mg once daily
Study: 3885424
Drug: naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 250 mg 3 times daily
Study: 29972757
Drug: Inotersen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotersen (300 mg weekly subcutaneous injections)
Study: 12137101
Drug: 5 short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 short breaks spaced hourly during cruise
Study: 9708636
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (FA; 500 mg/mq in 2‐hour intravenous infusion) and 5‐fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA) without hydroxyurea (HU) (arm A)
Study: 7619975
Drug: 35% CO2-65%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% CO2-65% O2 inhalation during early-follicular phase
Study: 7619975
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no CO2 inhalation)
Study: 485645
Drug: Clomiphene citrate,
Normalized name: ClomiPHENE Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate, 50 mg/day for 100 days
Study: 485645
Drug: Clomiphene citrate,
Normalized name: ClomiPHENE Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate, 50 mg/day
Study: 485645
Drug: Clomiphene therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene therapy
Study: 26796455
Drug: 180-degree laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180-degree laser photolysis (LP) treatment
Study: 26796455
Drug: 360-degree laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 360-degree laser photolysis (LP) treatment
Study: 14574515
Drug: Intravenous cholecystokinin
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholecystokinin (CCK-8) infusion at 10 ng/kg over 3 min
Study: 8221707
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 30 mg of nicardipine
Study: 25286986
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (ATII) infusion at a starting dose of 20 ng/kg/min, titrated to maintain MAP of 65 mmHg for 6 hours
Study: 25286986
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (ATII) infusion
Study: 21565321
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily
Study: 9491878
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy
Study: 9027267
Drug: Zafirlukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (20 mg twice daily)
Study: 7769301
Drug: Menfegol foaming
Normalized name: menfegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menfegol foaming tablets used once every other day
Study: 7769301
Drug: Menfegol foaming
Normalized name: menfegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menfegol foaming tablets used 1 time a day
Study: 7769301
Drug: Menfegol foaming
Normalized name: menfegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menfegol foaming tablets used 2 times a day
Study: 7769301
Drug: Menfegol foaming
Normalized name: menfegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menfegol foaming tablets used 4 times a day
Study: 7769301
Drug: Menfegol foaming
Normalized name: menfegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menfegol foaming tablets used 8 times a day
Study: 7769301
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets used < 8 times daily
Study: 7769301
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets used 8 times daily
Study: 2162749
Drug: (R)-propafenone 3
Normalized name: (+)-(r)-propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-propafenone 3 x 10(−6) mol/L
Study: 2162749
Drug: (S)-propafenone 3
Normalized name: (-)-(S)-Propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-propafenone 3 x 10(−6) mol/L
Study: 11450927
Drug: Community pharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacy consultation for head lice treatment
Study: 9503220
Drug: Somatostatin administration
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin administration over a 10-day period
Study: 15892276
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Control group)
Study: 3054094
Drug: Aspirin, 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 3.6 g/day
Study: 3054094
Drug: Diclofenac, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac, 150 mg/day
Study: 12914551
Drug: 5 micro
Normalized name: Filter Connector 5 micron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micro g/kg of APO
Study: 12914551
Drug: 10 micro
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micro g/kg of APO
Study: 10740546
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of inhalation anaesthetics
Study: 11561938
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg/day
Study: 1281905
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with subsequent autologous bone marrow transplantation (HDC/ABMT)
Study: 31248067
Drug: Usual Western‐style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Western‐style diet enriched with 60 g/day of a mixture of nuts (nut group; n = 43)
Study: 25018121
Drug: Once-weekly dulaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly dulaglutide (1.5 mg)
Study: 20332351
Drug: Once-daily liraglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily liraglutide (1.8 mg)
Study: 25018121
Drug: Once-weekly dulaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly dulaglutide
Study: 25018121
Drug: Once-daily liraglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily liraglutide
Study: 21915624
Drug: GMA adjusted
Normalized name: GMA-161
DrugBank: GMA-161 (DB15397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMA adjusted to patients' body weight (BW), 60 mL/kg
Study: 21915624
Drug: Routine GMA
Normalized name: GMA-161
DrugBank: GMA-161 (DB15397)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine GMA (fixed at 30 mL/min × 60 min)
Study: 20613676
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake (less than 500, 500 to 749, 750 to 999, 1,000 to 1,199, and 1,200 or greater mg/day)
Study: 12788862
Drug: Flutamide (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (125 mg/d) and Metformin (1275 mg/d)
Study: 8951297
Drug: IV immune
Normalized name: GLOBULIN,IMMUNE (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immune globulin treatment
Study: 17215848
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg plus Valsartan 160 mg
Study: 12132278
Drug: Basic analgesics
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic analgesics combined with on demand medication (group 2)
Study: 9660994
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (120 mg daily) with or without concomitant antiretroviral agents
Study: 9660994
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (120 mg daily)
Study: 7648767
Drug: Immediate-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation of racemic verapamil (240 mg)
Study: 7648767
Drug: Sustained-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulation of racemic verapamil (240 mg)
Study: 31672070
Drug: BBTI (Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBTI (Brief Behavioral Treatment for Insomnia)
Study: 23123046
Drug: short-term or
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short-term or long-term therapy
Study: 21372697
Drug: Nurse-led cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive-behavior therapy (CBT) for 6 weeks
Study: 19921983
Drug: Dutasteride 5
Normalized name: Dutasteride 500 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 5 mg/day for 5 weeks
Study: 19921983
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens 160 mg/day for 5 weeks
Study: 16309958
Drug: Ramelteon 16
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 16 mg
Study: 21955196
Drug: Ramelteon 32
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 32 mg
Study: 1302472
Drug: Chemotherapy alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alternating with radiotherapy (4 cycles of intravenous cisplatin 20 mg/m²/day for 5 days and fluorouracil 200 mg/m²/day for 5 days, alternating with radiotherapy in three 2-week courses of 20 Gy per course, 2 Gy per day, 5 days per week)
Study: 1302472
Drug: Chemotherapy alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alternating with radiotherapy
Study: 29320597
Drug: SPF 70
Normalized name: Coppertone Kids Sunscreen SPF 70
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 70 sunscreen applied at 1 mg/cm2
Study: 29320597
Drug: SPF 15
Normalized name: Carmex Original SPF 15
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 15 sunscreen applied at 2 mg/cm2
Study: 29320597
Drug: SPF 15
Normalized name: Carmex Original SPF 15
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 15 sunscreen applied at 1 mg/cm2
Study: 23008825
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative treatment before planned radical Wertheim hysterectomy
Study: 20353496
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (proton pump inhibitors or H(2)-receptor antagonists)
Study: 18671147
Drug: Albuterol Sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol Sulfate (90 micrograms/puff)
Study: 18671147
Drug: Albuterol/Ipratropium bromide
Normalized name: albuterol/ipratropium bromide 20/100 MCG/INHAL Metered Dose Inhalation Spray, 120 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/Ipratropium bromide (90 micrograms/puff/18 micrograms/puff)
Study: 12262389
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Depo-Provera and Depo-Testosterone
Study: 12262389
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of drug administration
Study: 12262389
Drug: Maintenance doses
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance doses of the drug
Study: 10859047
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with fibrin-stabilising factor XIII
Study: 15526508
Drug: Carvedilol, 12.5
Normalized name: Carvedilol, 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol, 12.5 mg/day for six days
Study: 3293257
Drug: Oral cyclosporine‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine‐A (CyA) 5 mg/kg/day for an additional 6 months (open trial)
Study: 22642697
Drug: Single 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 750 mg dose telaprevir with 600 mg rifampicin
Study: 22642697
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg every 8 h telaprevir with 600 mg efavirenz
Study: 21807759
Drug: Daclizumab (DAC)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab (DAC) high dose with interferon beta (IFNβ)
Study: 21807759
Drug: Daclizumab (DAC)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab (DAC) low dose with interferon beta (IFNβ)
Study: 16194003
Drug: IVR-administered Brief
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR-administered Brief Symptom Inventory (BSI)
Study: 16194003
Drug: Paper-and-pencil survey
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil survey administration
Study: 7802313
Drug: Buprenorphine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.01 mg/kg)
Study: 7802313
Drug: Nubain (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nubain (0.3 mg/kg)
Study: 16093747
Drug: Morphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.3 mg/kg)
Study: 2454140
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (1.0 to 3.0 ng/kg/min)
Study: 31220957
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% infusion on the day of embryo transfer and a second dose on the day of pregnancy test
Study: 31220957
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intralipid therapy)
Study: 26764317
Drug: Energy and
Normalized name: Energy And Endurance Testosterone UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy and protein supplementation (300 kcal/d, 15 g protein/d)
Study: 24225233
Drug: Weekly Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly Cetuximab (400 mg/m2 loading dose one week prior to radiotherapy followed by weekly 250 mg/m2)
Study: 24225233
Drug: Concurrent daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent daily Cisplatin (6 mg/m2) and radiotherapy (66 Gy in 24 fractions) without Cetuximab
Study: 11773508
Drug: 1000 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL/d of green tea
Study: 11773508
Drug: 1000 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL/d of black tea
Study: 2104075
Drug: Omeprazole 160
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 160 mg (loading dose of 80 mg)
Study: 6487498
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg
Study: 392623
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg prostaglandin E2
Study: 392623
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg prostaglandin E2
Study: 22209798
Drug: Trauma-focused cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive-behavioral therapy (TF-CBT)
Study: 31142219
Drug: Direct transfer
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct transfer to endovascular center (endovascular treatment stroke center)
Study: 28865351
Drug: Exogenous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous testosterone (topical gel)
Study: 2053167
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy
Study: 1455006
Drug: NO-EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NO-EPO therapy (Control)
Study: 3913378
Drug: Diclofenac (32.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (32.5 mg)
Study: 7017781
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg)
Study: 22723853
Drug: Benfluorex (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (150 to 450 mg/day)
Study: 22723853
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 to 45 mg/day)
Study: 20103455
Drug: Intramuscular phloroglucinol
Normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular phloroglucinol (4 mL)
Study: 20103455
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, 4 mL)
Study: 17762547
Drug: Novel ion
Normalized name: Sulfate ion
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel ion channel blockers targeting atrial-specific ion channels or a combination of ion channels.
Study: 17762547
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs inhibiting fibrosis, cellular hypertrophy, and improving cell-cell communication.
Study: 22999793
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation
Study: 8004580
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin treatment
Study: 8004580
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no heparin treatment)
Study: 8476405
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy
Study: 31393868
Drug: 3BNC117 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3BNC117 and 10-1074 at 10 mg/kg, one infusion
Study: 31393868
Drug: 3BNC117 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3BNC117 and 10-1074 at 3 mg/kg every 8 weeks
Study: 31393868
Drug: 3BNC117 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3BNC117 and 10-1074 at 10 mg/kg every 8 weeks
Study: 337478
Drug: Placebo infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions